HK1212995A1 - A method of purifying proteins - Google Patents
A method of purifying proteinsInfo
- Publication number
- HK1212995A1 HK1212995A1 HK16100830.6A HK16100830A HK1212995A1 HK 1212995 A1 HK1212995 A1 HK 1212995A1 HK 16100830 A HK16100830 A HK 16100830A HK 1212995 A1 HK1212995 A1 HK 1212995A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- purifying proteins
- purifying
- proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1722—Plasma globulins, lactoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4717—Plasma globulins, lactoglobulin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Marine Sciences & Fisheries (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261709342P | 2012-10-03 | 2012-10-03 | |
US13/803,525 US9534029B2 (en) | 2012-10-03 | 2013-03-14 | Method of purifying proteins |
AU2013203930A AU2013203930B2 (en) | 2012-10-03 | 2013-04-11 | A method of purifying proteins |
EP13170202 | 2013-06-03 | ||
PCT/US2013/062916 WO2014055552A1 (en) | 2012-10-03 | 2013-10-01 | A method of purifying proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1212995A1 true HK1212995A1 (en) | 2016-06-24 |
Family
ID=52824845
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16100830.6A HK1212995A1 (en) | 2012-10-03 | 2016-01-26 | A method of purifying proteins |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP2904005A1 (en) |
JP (2) | JP6370792B2 (en) |
KR (2) | KR102125695B1 (en) |
CN (2) | CN104968676A (en) |
CA (2) | CA3129057C (en) |
HK (1) | HK1212995A1 (en) |
SG (1) | SG11201501921SA (en) |
WO (1) | WO2014055552A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2887588T3 (en) * | 2015-08-13 | 2021-12-23 | Kamada Ltd | Compositions derived from Cohn's fraction paste and use thereof |
US20190276521A1 (en) * | 2016-03-29 | 2019-09-12 | Kyowa Hakko Kirin Co., Ltd. | Therapeutic agent for treatment of autoimmune diseases containing antibody binding to haptoglobin in blood and forming polyvalent immune complex as an active component |
AU2018314767B2 (en) * | 2017-08-08 | 2024-03-21 | Csl Behring Ag | Hemopexin formulations |
EP3783359B1 (en) * | 2018-04-18 | 2024-03-27 | Sekisui Medical Co., Ltd. | Haemoglobin analysis method |
EP3968988A1 (en) | 2019-05-17 | 2022-03-23 | Universität Zürich | Haptoglobin for use in treating an adverse secondary neurological outcome following a haemorrhagic stroke |
CN117136068A (en) | 2021-02-01 | 2023-11-28 | 瑞士杰特贝林生物制品有限公司 | Method for treating or preventing adverse secondary neurological consequences after hemorrhagic stroke |
US20240034749A1 (en) * | 2021-02-04 | 2024-02-01 | Green Cross Corporation | Method for purification of hemopexin and haptoglobin |
WO2024134608A1 (en) | 2022-12-22 | 2024-06-27 | Csl Behring Ag | Method of purifying hemopexin using mixed-mode chromatography |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5337406B2 (en) * | 1973-11-15 | 1978-10-09 | ||
GB1426039A (en) * | 1973-11-15 | 1976-02-25 | Green Cross Corp | Haptoglobin in aqueous solution and process for tits preparation |
US4129648A (en) * | 1977-11-21 | 1978-12-12 | Collier Harry O J | Method for reducing endogenous prostaglandin synthesis |
US4764369A (en) | 1983-07-14 | 1988-08-16 | New York Blood Center Inc. | Undenatured virus-free biologically active protein derivatives |
US4540573A (en) * | 1983-07-14 | 1985-09-10 | New York Blood Center, Inc. | Undenatured virus-free biologically active protein derivatives |
JPS6317899A (en) * | 1986-07-09 | 1988-01-25 | Green Cross Corp:The | Purification of haptoglobin |
JPH01305036A (en) * | 1988-05-31 | 1989-12-08 | Green Cross Corp:The | Heat-treatment of plasma protein component and drug preparation containing plasma protein component |
US5169936A (en) * | 1989-04-14 | 1992-12-08 | Biogen, Inc. | Protein purification on immobilized metal affinity resins effected by elution using a weak ligand |
US5138034A (en) * | 1989-07-12 | 1992-08-11 | The Green Cross Corporation | Method of fractionating plasma proteins |
FR2672604B1 (en) * | 1991-02-07 | 1995-05-05 | Pasteur Merieux Serums Vacc | PROCESS FOR ISOLATING HUMAN ALBUMIN FROM SURNANTANT IV, PARTICULARLY IV-4, OR FRACTION V OF COHN OR OF A SURNANTANT OR THE LIKE FRACTION. |
SE9301582D0 (en) * | 1993-05-07 | 1993-05-07 | Kabi Pharmacia Ab | PURIFICATION OF PLASMA PROTEINS |
DE19830914C1 (en) * | 1998-07-10 | 1999-06-24 | Centeon Pharma Gmbh | Preparation of a protein solution, especially albumin solution for use as blood volume substitute in emergency situations, and solution containing blood coagulation factors |
US6093804A (en) * | 1998-09-24 | 2000-07-25 | American National Red Cross | Method for purification of alpha-1 proteinase inhibitor |
US6815181B2 (en) * | 2001-07-09 | 2004-11-09 | Applera Corporation | Nucleic acid molecules encoding human secreted hemopexin-related proteins |
DE10211632A1 (en) | 2002-03-15 | 2003-10-09 | Aventis Behring Gmbh | Process for the separation of viruses from a protein solution by nanofiltration |
DE10215315A1 (en) * | 2002-04-05 | 2003-11-20 | Aventis Behring Gmbh Intellect | Human transferrin for the treatment of anemia of chronic disease (ACD) and functional iron deficiency |
AU2002307776A1 (en) * | 2002-04-16 | 2003-10-27 | Kamada Ltd. | Ultrapure transferrin for pharmaceutical compositions |
DE10261126A1 (en) | 2002-08-13 | 2004-03-04 | Aventis Behring Gmbh | Storage-stable, liquid fibrinogen formulation |
JP2004224793A (en) * | 2003-01-17 | 2004-08-12 | Research Corp Technologies Inc | Method of treating endometriosis |
JP2004256463A (en) * | 2003-02-26 | 2004-09-16 | Univ Waseda | Agent for inhibiting cell adhesion of polymorphonuclear leukocyte and method for inhibiting cell adhesion |
GB0423196D0 (en) * | 2004-10-19 | 2004-11-24 | Nat Blood Authority | Method |
US7291338B2 (en) * | 2005-03-09 | 2007-11-06 | Idexx Laboratories, Inc. | Method and device for detecting feline immunodeficiency virus |
WO2007132291A2 (en) * | 2006-05-15 | 2007-11-22 | Digilab, Inc. | Biomarkers for pre-form of type 2 diabetes and methods for detecting the presence of absence of a pre-form of type 2 diabetes |
WO2009025754A2 (en) * | 2007-08-17 | 2009-02-26 | Csl Behring Gmbh | Methods for purification of alpha-1-antitrypsin and apolipoprotein a-i |
EP2027875A1 (en) * | 2007-08-23 | 2009-02-25 | Octapharma AG | A Process for Isolation and Purification of a Target Protein free of Prion Protein (PrPSC) |
KR101426039B1 (en) * | 2008-09-11 | 2014-08-01 | 삼성테크윈 주식회사 | Apparatus and method for extracting feature point to recognize face/object |
FR2942233B1 (en) * | 2009-02-19 | 2015-03-13 | Lfb Biotechnologies | MEANS FOR PURIFYING BLOOD PLASMA PROTEIN, AND METHODS FOR ITS IMPLEMENTATION |
EP2236617A1 (en) * | 2009-03-31 | 2010-10-06 | Leukocare Ag | Methods of terminal sterilization of biofunctional compositions |
WO2011002070A1 (en) * | 2009-07-02 | 2011-01-06 | 協和発酵キリン株式会社 | Pharmaceutical composition for treating iron overload disorders or diseases on which the reduction in iron concentration is effective, which comprises gdf7/bmp12 protein |
ES2426098T3 (en) * | 2009-07-16 | 2013-10-21 | Institut National de la Santé et de la Recherche Médicale | Pharmaceutical compositions and their use in cancer treatment |
ES2360782B1 (en) * | 2009-07-28 | 2012-03-12 | Grifols, S.A. | Means for culturing mammalian cells comprising supernatant of stages of Cohn fractionation and use thereof. |
CN102471368A (en) * | 2009-08-11 | 2012-05-23 | 拜康有限公司 | Chromatographic processes and purified compounds thereof |
ES2545893T3 (en) * | 2010-04-20 | 2015-09-16 | Octapharma Ag | New stabilizing agent for pharmaceutical proteins |
WO2012050874A2 (en) * | 2010-09-28 | 2012-04-19 | Soares Miguel P | Targeting heme for the treatment of immune mediated inflammatory diseases |
-
2013
- 2013-10-01 JP JP2015535745A patent/JP6370792B2/en active Active
- 2013-10-01 CN CN201380051960.4A patent/CN104968676A/en active Pending
- 2013-10-01 CA CA3129057A patent/CA3129057C/en active Active
- 2013-10-01 KR KR1020157011544A patent/KR102125695B1/en active IP Right Grant
- 2013-10-01 WO PCT/US2013/062916 patent/WO2014055552A1/en active Application Filing
- 2013-10-01 EP EP13777203.4A patent/EP2904005A1/en not_active Withdrawn
- 2013-10-01 KR KR1020207017157A patent/KR102231613B1/en active IP Right Grant
- 2013-10-01 CA CA2886726A patent/CA2886726C/en active Active
- 2013-10-01 SG SG11201501921SA patent/SG11201501921SA/en unknown
- 2013-10-01 CN CN202110206879.5A patent/CN112717125A/en active Pending
-
2016
- 2016-01-26 HK HK16100830.6A patent/HK1212995A1/en unknown
-
2018
- 2018-07-10 JP JP2018130335A patent/JP6876655B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
KR102231613B1 (en) | 2021-03-25 |
CA3129057A1 (en) | 2014-04-10 |
CN112717125A (en) | 2021-04-30 |
JP6876655B2 (en) | 2021-05-26 |
WO2014055552A1 (en) | 2014-04-10 |
SG11201501921SA (en) | 2015-04-29 |
KR102125695B1 (en) | 2020-06-24 |
CA2886726A1 (en) | 2014-04-10 |
EP2904005A1 (en) | 2015-08-12 |
CN104968676A (en) | 2015-10-07 |
CA2886726C (en) | 2021-11-23 |
JP2018172426A (en) | 2018-11-08 |
JP6370792B2 (en) | 2018-08-08 |
KR20200075027A (en) | 2020-06-25 |
JP2015532301A (en) | 2015-11-09 |
KR20150063547A (en) | 2015-06-09 |
CA3129057C (en) | 2023-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20181357T1 (en) | Novel protein purification methods | |
HK1214833A1 (en) | A method of purifying therapeutic proteins | |
EP2883882A4 (en) | Protein purification method | |
GB201217772D0 (en) | Sequencing method | |
IL232558B (en) | Antibody purification method | |
PT2768857T (en) | Methods of purifying antibodies | |
ZA201305971B (en) | Method for the purification of biphephos | |
HRP20190030T1 (en) | Method of purifying an antibody | |
HK1212995A1 (en) | A method of purifying proteins | |
EP2727930A4 (en) | Method for purifying protein | |
SG11201405296QA (en) | Method for purifying acetonitrile | |
GB201222693D0 (en) | Novel method | |
SG10201606218WA (en) | Purified Proteins | |
EP2697245A4 (en) | Methods of purifying hydrophobin | |
GB201209082D0 (en) | Purification method | |
GB201220155D0 (en) | Method of manufacture | |
SG11201501216XA (en) | Method for purifying acetonitrile | |
LT3202769T (en) | Purification method for phosphaplatin compounds | |
EP2743258A4 (en) | Method for purifying levo-oxiracetam | |
SG2013017017A (en) | A method of separation | |
EP2737065A4 (en) | Protein production method | |
EP2762486A4 (en) | Method for purifying protein | |
GB201105407D0 (en) | Purification method | |
SG10201703786YA (en) | Nox removal method | |
GB201215942D0 (en) | Method of treatent |